Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Anterior Uveitis - Pipeline Insight, 2019 - ResearchAndMarkets.com By: Research and Markets via Business Wire News Releases April 19, 2019 at 05:49 AM EDT The "Anterior Uveitis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anterior Uveitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages: Clinical Non-clinical Inactive: Discontinued and/or Dormant Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Scope of the Report The report provides a snapshot of the pipeline development for Anterior Uveitis The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Anterior Uveitis The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Anterior Uveitis The report also covers the dormant and discontinued pipeline projects related to Anterior Uveitis Reasons to Buy Establish comprehensive understanding of the pipeline activity across this Anterior Uveitis to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Anterior Uveitis therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress Topics Covered1. Report Introduction2. Anterior Uveitis Overview3. Pipeline Therapeutics An Overview of Pipeline Products for Anterior Uveitis 4. Comparative Analysis5. Products in Clinical Stage Product Description Research and Development Product Development Activities 6. Products in Pre-Clinical and Discovery Stage Product Description Research and Development Product Development Activities 7. Therapeutic Assessment Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type 8. Inactive Products Product Description Research and Development Product Development Activities Companies Mentioned Abbvie Lux Biosciences Inc. Santen Pharmaceutical Co. Ltd. EyeGate Pharmaceuticals Inc. XOMA Corp. OphthaliX Inc. Enzo Biochem Inc. Apitope Inc. Sirion Therapeutics For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1m6eq0View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005050/en/ Contacts: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Immune Disorders Drugs, Optical Disorders Drugs Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Anterior Uveitis - Pipeline Insight, 2019 - ResearchAndMarkets.com By: Research and Markets via Business Wire News Releases April 19, 2019 at 05:49 AM EDT The "Anterior Uveitis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anterior Uveitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages: Clinical Non-clinical Inactive: Discontinued and/or Dormant Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Scope of the Report The report provides a snapshot of the pipeline development for Anterior Uveitis The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Anterior Uveitis The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Anterior Uveitis The report also covers the dormant and discontinued pipeline projects related to Anterior Uveitis Reasons to Buy Establish comprehensive understanding of the pipeline activity across this Anterior Uveitis to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Anterior Uveitis therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress Topics Covered1. Report Introduction2. Anterior Uveitis Overview3. Pipeline Therapeutics An Overview of Pipeline Products for Anterior Uveitis 4. Comparative Analysis5. Products in Clinical Stage Product Description Research and Development Product Development Activities 6. Products in Pre-Clinical and Discovery Stage Product Description Research and Development Product Development Activities 7. Therapeutic Assessment Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type 8. Inactive Products Product Description Research and Development Product Development Activities Companies Mentioned Abbvie Lux Biosciences Inc. Santen Pharmaceutical Co. Ltd. EyeGate Pharmaceuticals Inc. XOMA Corp. OphthaliX Inc. Enzo Biochem Inc. Apitope Inc. Sirion Therapeutics For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1m6eq0View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005050/en/ Contacts: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Immune Disorders Drugs, Optical Disorders Drugs